Skip to main content

Biogen’s stock blasts off after surprise reversal on Alzheimer’s drug, earnings beat

Shares of Biogen Inc. blasted off Tuesday, after the biotechnology company said its Alzheimer’s treatment is ready to start the regulatory approval process, and following third-quarter earnings that rose well-above expectations.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.